The following discussion and analysis of financial condition and results of
operations should be read in conjunction with our financial statements and
related notes included elsewhere in this report. This discussion contains
forward-looking statements that involve risks, uncertainties and assumptions.
See "Forward-Looking Statements."
Overview
Since January 30, 2017, following a change of control, we have been engaged in
the business of developing and marketing nutritional products that promote
wellness and a healthy lifestyle. Our business to date has involved the purchase
of products from three suppliers in the Republic of China and the sale of these
products to three unrelated customers, one of which accounted for all of our
sales in the quarters ended March 31, 2020, which were our only sales in the six
months ended June 30, 2020, and December 31, 2019, which were our only sales in
the year ended December 31, 2019. We did not have any sales during the three
months ended June 30, 2020 or first three quarters of the year ended December
31, 2019. We sell product in bulk to companies who may use our products as
ingredients in their products or sell the products they purchase from us to
their own customers.
All of our sales to date have been sales of cordyceps related products and, in
the quarter ended March 31, 2018, metallothionein MT-3 elizer. Cordyceps is a
fungus that is used in traditional Chinese medicine. Cordyceps sinensis has been
described as a medicine in old Chinese medical books and Tibetan medicine. It is
a rare combination of a caterpillar and a fungus and found at altitudes above
4500m in Sikkim. Our present inventory is for cordyseps products. The encoded
protein in metallothionein MT-3 is a growth inhibitory factor, and reduced
levels of the protein are observed in the brains of individuals with some
metal-linked neurodegenerative disorders such as Alzheimer's disease. We have
not sold metallothionein MT-3 elizer since the quarter ended March 31, 2018, and
we do not have any orders for metallothionein MT-3 elizer. We cannot assure you
that we will be able to sell metallothionein MT-3 elizer in the future. We may
also seek to market other products which we see as complimentary to our present
products; however, we have not entered into negotiations with respect to the
distribution of other products and we cannot assure you that we will be able to
market any other products.
All of our revenue for the six months ended June 30, 2020 represents sales to
one customer which were made during the three months ended March 31, 2020. There
were no sales during the three months ended June 30, 2020. We believe that our
failure to sell products in the three months ended June 30, 2020 resulted
substantially from the COVID - 19 pandemic and actions taken by governments to
address the pandemic. We believe our failure to generate sales reflects a
downturn in the market in the PRC for cordyseps products as well as the
political conditions in Hong Kong, and we cannot assure you that the market will
improve. We also cannot assure you the political instability in Hong Kong will
not affect our sales, since our customers in 2017 and 2018 were Hong Kong based
customers who sold their products in the People's Republic of China (the "PRC")
and none of these customers has made purchases from us since the quarter ended
December 31, 2018. We cannot assure you that these factors will not affect our
ability to generate revenues in the future and, to the extent that any of these
factors affects our ability to generate revenue, we may not be able to continue
in business.
At present, we have no full-time employees. Our only employee is our chief
executive officer who works for us on a part-time basis, and all of our sales to
date have been made by our chief executive officer. We plan to develop a
marketing program pursuant to which we will seek to:
· market raw materials to customers, primarily in Hong Kong, who would use
our products as an ingredient on their products;
· enter into agreements with customers pursuant to which we would develop
and supply products which include our ingredients and which meet the
specifications of the customer;
· develop one or more products which we would sell to retail outlets which
would sell our products to their customers or sell the products directly
to retail customers as on-line sales.
12
Table of Contents
We do not presently have either a marketing staff or any manufacturing
facilities. We intend to develop a marketing staff by hiring a marketing manager
and engaging independent sales representatives or hiring sales and marketing and
sales personnel or a combination of independent representatives and sales staff.
We cannot assure you that we will be able to engage the necessary qualified
personnel or to implement an effective marketing program.
We face significant risks in implementing our business plan including, but not
limited to, our ability to raise the necessary financing either through the sale
of debt or equity securities or through a loan facility, our ability to increase
our customer base and supply chain, our ability to increase our gross margins,
our ability to hire and retain qualified research and development, marketing and
administrative personnel, our ability to develop products and to market in the
United States and other western markets any products we may develop, our ability
to comply with any government regulations relating to the manufacture,
distribution and marketing any products we develop. We cannot assure you that we
can or will develop any products or generate revenue or profits in the future.
Although our business plan initially contemplated that we would conduct research
and development on our own proprietary products based on cordyceps sinensis, to
date we have neither commenced such activities nor take any preliminary steps
with respect to such activities. We do not presently have the funds necessary
for us to engage in such activities, and we cannot assure you that we will be
able to commence any research and development activities or that any such
activities that we may undertake will be successful.
We require funds for our operations. At June 30, 2020, we had $381cash and cash
equivalents, $938,000 of inventory of cordyceps products. Although we may seek
to raise funds in the equity market, we have no agreements or understandings
with respect to any funding and we can give no assurance as to the availability
or terms of any such financing. Because of our financial condition, the lack of
sales in the three months ended June 30, 2020 or first nine months of 2019 and
only modest sales in the fourth quarter of 2019 and the first quarter of 2020,
our reliance of sales primarily of one product, along with the absence of an
active market for our stock and our market capitalization in relation to our
financial performance, together with risk related to the COVID-19 pandemic and
the political and legal situation in Hong Kong, it may be difficult for us to
raise funds in the equity market, and, if we are able to raise funds our
stockholders may suffer significant dilution.
To the extent that we implement our business plan, we anticipate that we will
incur marketing and other expenses without any assurance that such expenses will
generate any significant revenue or net income. Because of our cash position, we
may use equity-based compensation for our employees and independent contractors.
In August 2020, we adopted our 2020 long-term incentive plan, pursuant to which
up to 12,000,000 shares can be issued. In order to pay cash expenses, we may
have to rely on loans from stockholders or related parties, although we do not
have any agreements or understandings at this time.
Effects of COVID-19
Since our products are purchased by customers in Hong Kong as one ingredient of
a product to be sold to their customers, our business has been and may continue
to be impacted by the effects of the COVID-19 pandemic and the actions taken by
the governments of the PRC, Hong Kong and the Republic of China ("Taiwan") as
they effect manufacturers and their customers. Since we had modest sales in the
three months ended March 31, 2020 as well as the year ended December 31, 2019,
with sales in only the last quarter of 2019, we cannot predict the effect of
COVID-19 on our business. A prolonged outbreak could have a material adverse
impact on our financial results and business operations. Factors relating to
COVID-19 which significantly contributed to our lack of revenue in the three
months ended June 30, 2020, may affect us and the market for our products
include, but are not limited to, the following.
· The effect of COVID-19 on the ability of our customers and potential
customers to manufacture products.
· The financial health of our potential customers.
· Since our customers use our products as an ingredient in their products,
the inability of the customer to obtain other ingredients may affect their
willingness or ability to purchase our product.
· The ability of our customers to ship their products to China and the
ability of their customers to distribute product to retail markets.
13
Table of Contents
· The willingness or ability of the ultimate purchasers in the PRC and any
other countries to which our customers sell products to purchase products
with our ingredients and their perception as to whether the products may
have beneficial effects to them.
· The extent to which any quarantine which may be imposed affects the
willingness or ability of consumers to purchase products with our
ingredients.
· The perceived benefit, if any, to consumers of products with our
ingredients.
· The extent to which the purchase of products with our ingredients is a low
priority item for a population whose disposable income may have decreased
as a result of COVID-19 and the steps taken by governments to curb the
spread of infection.
Results of Operations
Three and Six Months Ended June 30, 2020 and 2019.
For the three months ended June 30, 2020, we had no revenue, operating expenses
of $62,771, primarily professional fees relating to our status as a public
company, interest expense of $928 and a net loss of $63,699, or $(0.00) per
share (basic and diluted).
For the three months-ended June 30, 2019, we had no revenues, operating expenses
of $68,092, primarily professional fees related to our status as a public
company, interest expense of $609, a loss before income taxes of $68,701, an
income tax credit of $17,877, and a net loss of $50,824 or $(0.00) per share
(basic and diluted).
For the six months ended June 30, 2020, we had revenue of $687,964, representing
sales of cordyceps products from one customer. Our cost of revenue was $528,560,
our gross profit was $159,404, and our gross margin was 23.17%. Our operating
expenses were $140,618, primarily professional fees relating to our status as a
public company, our interest expense was $1,369 and we had net income of
$17,417, or $0.00 per share (basic and diluted).
For the six months ended June 30, 2019 we had no revenue, operating expenses of
$282,858, primarily stock-based compensation to consultants of $148,395, and
professional fees relating to our status as a public company, interest expense
of $717, a loss before income tax credit of $283,575, an income tax credit of
$63,001, and a net loss of $220,574, or $(0.00) per share (basic and diluted).
Because of our dependence on a few customers, one of which accounted for all of
our sales since January 1, 2019, our revenue in any quarter is dependent upon
both the timing of orders from customers and the delivery of products from our
suppliers.
Liquidity and Capital Resources
The following table summarizes our changes in working capital from December 31,
2019 to June 30, 2020:
December 31,
June 30, 2020 2019 Change % Change
Current assets $ 957,381 $ 879,471 $ 77,910 8.9 %
Current liabilities $ 171,268 $ 111,541 $ 59,727 53.5 %
Working capital $ 786,113 $ 767,930 $ 18,183 2.4 %
Our principal current asset is inventory, which was $938,000 at June 30, 2020
and $878,560 at December 31, 2019. To the extent that we are not able to sell
our inventory, our working capital will be materially impaired.
14
Table of Contents
The following table summarizes our cash flows for the six months ended June 30,
2020 and 2019:
Six Months Ended June 30,
2020 2019
Cash (used in) operating activities $ (97,845 ) $ (137,511 )
Cash provided by financing activities
97,315 100,135
Cash and cash equivalents end of period 381 231
Cash used in operating activities of $97,845 for the six months ended June 30,
2020 reflected primarily our net income of $17,417 decreased primarily by an
increase in inventory of $59,440, a decrease in accounts payable and accrued
expenses of $22,762, and a decrease of deferred revenue of $17,464 and an
increase in prepaid expenses of $12,000.
Cash used by operating activities of $137,511 for the six months ended June 30,
2019 reflected primarily our net loss of $220,574, decreased primarily by
stock-based compensation of $148,395, deferred revenue of $20,000 and a deferred
tax asset of $10,070, and increased by an adjustment in income tax payable
$73,071 and income tax payable of $19,156.
Our cash used in financing activities of $97,315 for the six months ended June
30, 2020 and $100,135 for the six months ended June 30, 2019 represented
advances from related parties.
Going Concern
The accompanying unaudited financial statements have been prepared assuming that
we will continue as a going concern, which contemplates the realization of
assets and the liquidation of liabilities in the normal course of business. We
had minimal cash as of June 30, 2020 and did not generate cash from its
operation for the six months ended June 30, 2020 and we had no sales in the
three months ended June 30, 2020 and, during the year ended December 31, 2019,
we only had sales in the fourth quarter. These factors, among others, raise
substantial doubt about our ability to continue as a going concern. The
financial statements do not include any adjustments that might result from the
outcome of this uncertainty.
We propose to fund operations through sales of its products and equity financing
arrangements. We plan to introduce a marketing effort to market our products,
however, we cannot give any assurance as to our ability to implement a marketing
program or to generate revenue or net income from these efforts. Further, we did
not have any sales during the three months ended June 30, 2020, do not have any
agreements or understanding with respect to any financing and, because of the
lack of sales and the absence of any active trading market for our common stock,
our financial condition and our lack of an operating history, we may not be able
to raise funds for capital expenditures, working capital and other cash
requirements. Our ability to implement our proposed marketing plan may be
affected by the COVID-19 pandemic and actions taken by governments to address
the pandemic as well as political events and legislation in Hong Kong. If we
cannot generate revenue from our products, we may not be able to continue in its
business.
Critical Accounting Policy and Estimates
Our critical accounting policies are disclosed in Note 2 or Notes to Financial
Statements.
Recent Accounting Pronouncements
Management has considered all recent accounting pronouncements. Our management
believes that these recent pronouncements will not have a material effect on our
financial statements.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have or are reasonably
likely to have a current or future effect on our financial condition, changes in
financial condition, revenues or expenses, results of operations, liquidity,
capital expenditures or capital resources that is material to investors.
15
Table of Contents© Edgar Online, source Glimpses
ACRO BIOMEDICAL CO., LTD. 
